Caught in a loop: Glucagon-like peptide-1 agonists and weight loss technology as a commercial determinant of health
DOI:
https://doi.org/10.55016/mxhey898Keywords:
Weight loss, Glucagon-like peptide-1 agonists, pharmaceuticalization, recursivity, fatnessAbstract
We examined how companies that manufacture weight loss pharmaceuticals, Glucagon-like peptide-1 agonists, along with the non-profits they sponsor and their public facing websites, operate as commercial determinants of health through the discourses they produce online. Data were extracted from organization websites and uploaded into NVivo 15 for multimodal critical discourse analysis. Discourses identified were not new but recursively constructed ‘obesity’ through a medicalized discourse grounded in scientific authority, as diseased, and needing treatment, which reproduces discourses of other weight loss ‘cures’. The Body Mass Index was presented as an objective, but limited, metric to classify bodies, rendering health risk quantifiable. Structural determinants of health were acknowledged but absorbed into a medicalized framework. Across all sources, healthcare professionals were positioned as saviours, guiding individuals toward successful outcomes. A final discourse, present only on pharmaceutical and non-profit sites, framed commercial pharmaceutical intervention as necessary to ease the economic burden of ‘obesity’ on public services. In conclusion, these websites contribute to the pharmaceuticalization of weight and the commercialization of bodily dissatisfaction and health. Although they attempt to project themselves as anti-stigmatizing, these discourses remain highly individualized, clinically focused, and reproduce and reinforce weight-based stereotypes.
References
Alexis, A. C. (2021, June 14th). What are food deserts? All you need to know. Healthline. https://www.healthline.com/nutrition/food-deserts#solutions
Bacon, L., & Aphramor, L. (2011) Weight science: Evaluating the evidence for a paradigm shift. Nutrition Journal, 10, 9. https://doi.org/10.1186/1475-2891-10-9
Basinger, E. D., & Watford, M. L. (2026) History repeating itself: Anti-fat narratives in the ozempic and Fen-Phen eras. Fat Studies, 15(2), 90-99. https://doi.org/10.1080/21604851.2026.2632416
Batt, S. (2019) Health Advocacy Inc.: How pharmaceutical funding changed the breast cancer movement. University of British Columbia Press.
Bell, K. (2016) Health and other unassailable values. Routledge
Bombak, A. (2014) Obesity, health at every size, and public health policy. American Journal of Public Health, 104(2), e60-e67. https://doi.org/10.2105/AJPH.2013.301486
Bombak, A. (2023) How pharmaceutical companies misappropriate fat acceptance. Critical Public Health, 33(5), 856-863. https://doi.org/10.1080/09581596.2023.2273201
Bombak, A. E., Adams, L., & Thille, P. (2022) Drivers of medicalization in the Canadian Adult Obesity Clinical Practice Guidelines. Canadian Journal of Public Health, 113(5), 743-748. https://doi.org/10.17269/s41997-022-00662-4
Bombak, A. E., Meadows, A., & Billette, J. (2019) Fat acceptance 101: Midwestern American women’s perspective on cultural body acceptance. Health Sociology Review, 28(2), 194-208. https://doi.org/10.1080/14461242.2019.1604150
Brady, J., & Beausoleil, N. (2018) A response to “A critical analysis of obesity prevention policies and strategies”. Canadian Journal of Public Health, 108(5-6), e630-e632. https://doi.org/10.17269/cjph.108.6520
Canadian Medical Association, & Abacus Data (2025) Canadian Medical Association 2025 health and media tracking survey. The Association. https://digitallibrary.cma.ca/link/digitallibrary761
Casazza, K., Fontaine, K. R., Astrup, A., Birch, L. L., Brown, A. W., Bohan Brown, M. M., … & Allison, D. B. (2013) Myths, presumptions, and facts about obesity. New England Journal of Medicine, 368(5), 446-454. https://doi.org/10.1056/NEJMsa1208051
Chamarthi, V. S., & Daley, S. F. (2025) Obesity as a chronic disease: Epidemiology and pathophysiologic insights. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK618380/
Clegg, R., & Jennings, H. (2025, December 20th). Weight-loss jabs: What happens when you stop? BBC. https://www.bbc.com/news/articles/cn98pdpyjz5o
Colls, R., & Evans, B. (2014) Making space for fat bodies? Progress in Human Geography, 38(6), 733-753. https://doi.org/10.1177/0309132513500373
Conrad, P. (2005) The shifting engines of medicalization. Journal of Health and Social Behavior, 46(1), 3-14. https://doi.org/10.1177/002214650504600102
Conrad, P., & Tan, C. (2014) Autism, the internet, and medicalization. In P. Wehling, W. Viehöver, & S. Koenen (Eds.), The public shaping of medical research: Patient associations, health movements and biomedicine (pp. 111-131). Routledge. https://doi.org/10.4324/9781315741871
Cooper, C. (2016) Fat activism: A radical social movement. HammerOn Press.
Creswell, J. W., & Poth, C. N. (2017) Qualitative inquiry & research design: Choosing among five approaches (4th ed.). Sage Publications.
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., … & Lingvay, I. (2021) Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): A randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971-984. https://doi.org/10.1016/s0140-6736(21)00213-0
Fairclough, N. (1989) Language and power. Longman Inc.
Farrell, A. E. (2011) Fat shame: Stigma and the fat body in American culture. New York University Press.
Farrell, L. C., Warin, M. J., Moore, V. M., & Street, J. M. (2016) Socio-economic divergence in public opinions about preventive obesity regulations: Is the purpose to 'make some things cheaper, more affordable' or to 'help them get over their own ignorance'? Social Science & Medicine, 154, 1-8. https://doi.org/10.1016/j.socscimed.2016.02.028
Flegal, K. M., Kit, B. K., Orpana, H., & Graubard, B. I. (2013) Association of all-cause mortality with overweight and obesity using standard Body Mass Index categories: A systematic review and meta-analysis. The Journal of the American Medical Association, 309(1), 71-82. https://doi.org/doi:10.1001/jama.2012.113905
Fothergill, E., Guo, J., Howard, L., Kerns, J. C., Knuth, N. D., Brychta, R., … & Hall, K. D. (2016) Persistent metabolic adaptation 6 years after “The Biggest Loser” competition. Obesity, 24(8), 1599-1821. https://doi.org/10.1002/oby.21538
Foucault, M. (1975) Discipline and punish: The birth of the prison. Vintage Books.
Gaesser, G. (2009) Is “permanent weight loss” an oxymoron? The statistics on weight loss and the National Weight Control Registry. In E. Rothblum & S. Solovay (Eds.), Biopolitics and the 'obesity epidemic' (pp. 37-40). New York University Press.
Gard, M., & Wright, J. (2005) The obesity epidemic: Science, morality and ideology. Routledge.
Gilmore, A. B., Fabbri, A., Baum, F., Bertscher, A., Bondy, K., Chang, H-J., … & Thow, A. M. (2023) Defining and conceptualising the commercial determinants of health. The Lancet, 401(10383), 1194-1213. https://doi.org/10.1016/S0140-6736(23)00013-2
Gleason, P., Marshall, L., Urick, B., Yang, Q., & Leslie, S. (2024b) Year-two real-world analysis of glucagon-like peptide-1 agonist (GLP-1) obesity treatment adherence and persistency. Prime Therapeutics. https://www.primetherapeutics.com/wp-content/uploads/2024/07/Prime-MRx-GLP-1-Year-Two-Study-Abstract-FINAL-7-10.pdf (Accessed 11 Nov 2026
Gleason, P. P., Urick, B. Y., Marshall, L. Z., Friedlander, N., Qiu, Y., & Leslie, R. S. (2024a) Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes. Journal of Managed Care & Specialty Pharmacy, 30(8), 860-867. https://doi.org/10.18553/jmcp.2024.23332
Godley, J., & McLaren, L. (2010) Socioeconomic status and body mass index in Canada: Exploring measures and mechanisms. The Canadian Review of Sociology, 47(4), 381-403. https://doi.org/10.1111/j.1755-618x.2010.01244.x
Guthman, J. (2024) The problem with solutions: Why Silicon Valley can't hack the future of food. University of California Press. https://doi-org.proxy.hil.unb.ca/10.1525/9780520402683
Hacking, I. (1995) The looping effects of human kinds. In D. Sperber, D. Premack, & A. J. Premack (Eds.), Causal cognition: A multidisciplinary debate (pp. 351–394). Clarendon Press/Oxford University Press.
Hall, K. D., Heymsfield, S. B., Kemnitz, J. W., Klein, S., Schoeller, D. A., & Speakman, J. R. (2012) Energy balance and its components: Implications for body weight regulation. American Journal of Clinical Nutrition, 95(4), 989-994. https://doi.org/10.3945/acjn.112.036350
Health Canada (2019, November 25th) Canadian guidlnes for body weight classification in adults. Questions and answers for the public. Government of Canada. https://www.canada.ca/en/health-canada/services/food-nutrition/healthy-eating/healthy-weights/canadian-guidelines-body-weight-classification-adults/questions-answers-public.html#a1
Hebert, J. R., Allison, D. B., Archer, E., Lavie, C. J., & Blair, S. N. (2013) Scientific decision making, policy decisions, and the obesity pandemic. Mayo Clinic Proceedings, 88(6), 593-604. https://doi.org/10.1016/j.mayocp.2013.04.005
Holden, C. (2000) NEJM admits breaking its own tough rules. Science, 287(5458), 1573. https://doi.org/10.1126/science.287.5458.1573a
Ikeda, J., Amy, N. K., Ernsberger, P., Gaesser, G. A., Berg, F. M., Clark, C. A., Parham, E. S., & Peters, P. (2005) The national weight control registry: A critique. Journal of Nutrition Education and Behavior, 37(4), 203-205. https://doi.org/10.1016/s1499-4046(06)60247-9
Jensen, S. D., Sandbæk, A., Bruun, J. M., & Andreassen, P. (2025) Tinkering with weight loss medication in clinical encounters: An ethnographic study. Social Science & Medicine, 384, 118538. https://doi.org/10.1016/j.socscimed.2025.118538
Jutel, A. (2006) The emergence of overweight as a disease entity: Measuring up normality. Social Science & Medicine, 63(9), 2268-2276. https://doi.org/10.1016/j.socscimed.2006.05.028
Jutel, A. (2009) Doctor's orders: Diagnosis, medical authority, and the exploitation of the fat body. In J. Wright & V. Harwood (Eds.), Biopolitics and the 'obesity epidemic' (pp. 60-77). Routledge.
Kaczynski, D., Salmona, M., & Smith, T. (2014) Qualitative research in finance. Australian Journal of Management, 39(1), 127-135. https://doi.org/10.1177/0312896212469611
Kirkland, A. (2011) The environmental account of obesity: A case for feminist skepticism. Signs, 36(2), 463-485. https://doi.org/10.1086/655916
Kollewe, J. (2025, July 12th) Microdosing: How ‘off-label’ use of weight loss jabs is spreading from US to UK. The Guardian. https://www.theguardian.com/business/2025/jul/12/microdosing-weight-loss-jabs-off-label-glp-1-mountjaro
Kwan, S., & Graves, J. (2013) Framing fat: Competing constructions in contemporary culture. Rutgers University Press.
LeBesco, K. (2004) Revolting bodies? The struggle to redefine fat identity. University of Masschusetts Press.
Liss, D., Cherupally, M., O’Brien, M., Kang, R., Aikman, C., Wallia, A., … & Ackermann, R. T. (2023) Treatment modification after initiating second line medication for type 2 diabetes. The American Journal of Managed Care, 29(12), 661-668. https://doi.org/10.37765/ajmc.2023.89466
Lupton, D. (1995) The imperative of health: Public health and the regulated body. Sage Publications.
Machin, D., & Mayr, A. (2012) How to do critical discourse analysis: A multimodal introduction. Sage Publications.
MacLean, P. S., Bergouignan, A., Cornier, M. A., & Jackman, M. R. (2011) Biology's response to dieting: The impetus for weight regain. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 301(3), R581-R600. https://doi.org/10.1152/ajpregu.00755.2010
Manavis, S. (2024, September 27th) The Ozempic craze and the limitations of liberal feminism. New Statesman. https://www.newstatesman.com/comment/2024/09/the-conversation-around-ozempic-is-more-toxic-than-ever
Mann, T., Tomiyama, A. J., Westling, E., Lew, A. M., Samuels, B., & Chatman, J. (2007) Medicare's search for effective obesity treatments: Diets are not the answer. American Psychologist, 62(3), 220-233. https://doi.org/10.1037/0003-066X.62.3.220
McKittrick, K (2021) Dear science and other stories. Duke University Press.
McPhail, D. (2017) Contours of the nation: Making obesity and imagining Canada, 1945-1970. University of Toronto Press.
Meadows, A. & Daníelsdóttir, S. (2016) What’s in a word? On weight stigma and terminology. Frontiers in Psychology, 7, 1527. https://doi.org/10.3389/fpsyg.2016.01527
Medvedyuk, S., Ali, A., & Raphael, D. (2018) Ideology, obesity and the social determinants of health: A critical analysis of the obesity and health relationship. Critical Public Health, 28(5), 573-585. https://doi.org/10.1080/09581596.2017.1356910
Meeuf, R. (2016) Class, corpulence, and neoliberal citizenship: Melissa McCarthy on Saturday Night Live. Celebrity Studies, 7(2), 137-153. https://doi.org/10.1080/19392397.2015.1044758
Mialon, M. (2020) An overview of the commercial determinants of health. Globalization and Health, 16, 74. https://doi.org/10.1186/s12992-020-00607-x
Monaghan, L. F., Bombak, A. E., & Rich, E. (2018) Obesity, neoliberalism and epidemic psychology: Critical commentary and alternative approaches to public health. Critical Public Health, 28(5), 498-508. https://doi.org/10.1080/09581596.2017.1371278
Monaghan, L. F., Rich, E., & Bombak, A. E. (2022) Rethinking obesity: Critical perspectives in crisis times. Routledge.
Mundy, A., & Rosenberg, C. E. (2001) Dispensing with the truth: The victims, the drug companies, and the dramatic story behind the battle over Fen-Phen. St. Martin's Press.
National Institute for Health and Care Excellence (2025, August 5th ). People need support to keep weight off after treatment ends. https://www.nice.org.uk/news/articles/people-need-support-to-keep-weight-off-after-treatment-ends (Accessed 12 January 2026)
Nature Medicine (2024) Are GLP-1 drugs really for everybody? Nature Medicine, 30(11), 3029.
https://doi.org/10.1038/s41591-024-03382-z
Novo Nordisk (n.d.) Annual report 2025: Financial performance. Novo Nordisk. https://annualreport.novonordisk.com/2025/strategic-aspirations/financial-performance.html. (Accessed 17 April 2026)
Novo Nordisk (2023, December) Weight-loss prescription medication: Wegovy® (SEMAGLUTIDE) injection 2.4 mg. http://www.wegovy.com (Accessed 17 Feb 2024)
Obesity Action Coalition (n.d.) Corporate council. https://www.obesityaction.org/corporate-council/
Obesity Canada (2023, November 23th) Consensus statement: Body Mass Index. Obesity Canada. https://obesitycanada.ca/news/consensus-statement-body-mass-index-bmi/ (Accessed 15 Nov 2026)
Obesity Canada (n.d.-a) Canadian Adult Obesity Clinical Practice Guidelines. Obesity Canada. https://obesitycanada.ca/healthcare-professionals/adult-clinical-practice-guideline/
Obesity Canada (n.d.-b) Partnering organizations. Obesity Canada. https://obesitycanada.ca/about/partners/
Petersen, A., & Lupton, D. (1996) The new public health: Health and self in the age of risk. Sage Publications.
Quinn, D. M., Puhl, R. M., Reinka, M. A., & Funderburk, L. (2020) Trying again (and again): Weight cycling and depressive symptoms in U.S. adults. PLoS One, 15(9), e0239004. https://doi.org/10.1371/journal.pone.0239004
Rasmussen, N. (2012) Weight stigma, addiction, science, and the medication of fatness in mid-twentieth century America. Sociology of Health & Illness, 34(6), 880-895. https://doi.org/10.1111/j.1467-9566.2011.01444.x
Rasmussen, N. (2015) Stigma and the addiction paradigm for obesity: Lessons from 1950s America. Addiction, 110(2), 217 - 225. https://doi.org/10.1111/add.12774
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., … & Dicker, D. (2021) Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial. The Journal of the American Medical Association, 325(14), 1414-1425. https://doi.org/10.1001/jama.2021.3224
Rubino, F., Cummings, D. E., Eckel, R. H., Cohen, R. V., Wilding, J. P. H., Brown, W. A., … & Mingrone, G. (2025) Definition and diagnostic criteria of clinical obesity. The Lancet Diabetes & Endocrinology, 13(3), 221-262. https://doi.org/10.1016/S2213-8587(24)00316-4
Shor, R., Mihalache, A., Noori, A., Shor, R., Kohly, R. P., Popovic, M. M., & Muni, R. H. (2025) Glucagon-like peptide-1 receptor agonists and risk of neovascular age-related macular degeneration. The Journal of the American Medical Association Ophthalmology, 143(7), 587-594. https://doi.org/10.1001/jamaophthalmol.2025.1455
Shu, Y., He, X., Wu, P., Liu, Y., Ding, Y., & Zhang, Q. (2022) Gastrointestinal adverse events
associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system. Frontiers in Public Health, 10, 996179. https://doi.org/10.3389/fpubh.2022.996179
Sodhi, M., Rezaeianzadeh, R., Kezouh, A., Etminan, M. (2023) Risk of gastrointestinal adverse
events associated with glucagon-like peptide-1 receptor agonists for weight loss. The Journal of the American Medical Association, 330(18), 1795–1797. https://doi.org/10.1001/jama.2023.19574
Strings, S. (2019) Fearing the black body: The racial origins of fat phobia. New York University Press.
Tomiyama, A. J., Hunger, J. M., Nguyen-Cuu, J., & Wells, C. (2016) Misclassification of cardiometabolic health when using body mass index categories in NHANES 2005-2012. International Journal of Obesity, 40(5), 883-886. https://doi.org/10.1038/ijo.2016.17
Tylka, T. L., Annunziato, R. A., Burgard, D., Daníelsdóttir, S., Shuman, E., Davis, C., & Calogero, R. M. (2014) The weight-inclusive versus weight-normative approach to health: Evaluating the evidence for prioritizing well-being over weight loss. Journal of Obesity, 2014, 983495. https://doi.org/10.1155/2014/983495
U of T News (2021, Feb 24th) Novo Nordisk and the University of Toronto announce a combined C$40-million investment to address diabetes and chronic disease prevention. University of Toronto. https://www.utoronto.ca/news/novo-nordisk-and-university-toronto-announce-combined-c40-million-investment-address-diabetes (Accessed 19 September 2026)
Wang, X., & Cohen, R. A. (2023) Health information technology use among adults: United States, July–December 2022. NCHS Data Brief, no 482. U.S. Department Of Health And Human Services. https://dx.doi.org/10.15620/cdc:133700.
Warin, M., & Zivkovic, T. (2019) Fatness, obesity, disadvantage in the Australian suburbs: Unpalatable politics. Palgrave McMillan.
Weatherall, D. (2000) Academia and industry: Increasingly uneasy bedfellows. The Lancet, 355, 1574. https://doi.org/10.1016/S0140-6736(00)02211-X
West, S., Scragg, J., Aveyard, P., Oke, J. L., Willis, L., Haffner, S. J. P., … & Koutoukidis, D. A. (2026) Weight regain after cessation of medication for weight management: Systematic review and meta-analysis. BMJ, 392, e085304. https://doi.org/10.1136/bmj-2025-085304
Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., … & Wicklum, S. (2020) Obesity in adults: A clinical practice guideline. Canadian Medical Association Journal, 192(31), E875. https://doi.org/10.1503/cmaj.191707
Wilding, J. P. H., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konakli, K., … & Kushner, R. F. (2022) Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553-1564. https://doi.org/10.1111/dom.14725
Williams, S. J., Martin, P., & Gabe, J. (2011) The pharmaceuticalisation of society? A framework for analysis. Sociology of Health and Illness, 33(5), 710-725. https://doi.org/10.1111/j.1467-9566.2011.01320.x
Yates-Doerr, E. (2013) The mismeasure of obesity. In M. McCullough & J. Hardin (Eds), Reconstructing obesity: The meaning of measures and the measure of meanings (pp. 49-70). Berghahn Books.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Andrea Bombak, Emily Paul, Braeden Martin , Ashley Morehouse, Taylor McAulay, Megan Warin, Natalie Riediger

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
All articles in the Journal of Critical Public Health are published under a CC-BY-NC-ND license, or a CC-BY license if authors or their funders require this. The default CC-BY-NC-ND license means that authors and users may copy and distribute the material in any medium or format in un-adapted form only, for non-commercial purposes only, and only so long as proper credit is given (as is customary in academic work). Authors retain copyright of their work published in Journal of Critical Public Health and full publishing rights without restrictions